Mono Pharmacare (MONOPHARMA)

Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At ₹12.90, Mono Pharmacare has a market cap of only ₹23 crore. That is small enough to be ignored by institutional investors, and after looking at the numbers, I understand why. Sales fell 23.94% and profits collapsed 99.13%; the latest quarter shows sales of ₹66 crore but net profit of ₹0 crore. A Piotroski F-Score of 3 out of 9 tells me the business is financially stressed, not strengthening. The P/E of 27.67 looks like a normal multiple, but with earnings virtually gone, that multiple is meaningless until we see a real recovery. ROCE of 11% shows the underlying capital base can produce some return, but a zero bottom line in the current quarter means shareholders are not seeing that return. There is no dividend to reward patience. On the positive side, quarterly sales of ₹66 crore dwarf the ₹23 crore market cap, suggesting a substantial operating base; if management can stabilize margins, the operating leverage could be enormous. But a Graham-style investor does not pay even a low price for a business with falling sales, no current earnings, and a 3/9 F-Score. I need evidence of a turnaround: several quarters of sequential margin improvement, positive net profit, and controlled debt. Until then, this is a show-me story, not an investment. It belongs in the too-hard pile.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer